2/23/2022 7:15:18 AM
Bausch Health Companies Q4 EPS $0.19 Vs. Loss/shr $0.43 Prior Year
1/20/2022 7:03:16 AM
Yehia Hashad To Join Bausch + Lomb As EVP Of Research & Development And Chief Medical Officer
1/18/2022 7:49:52 AM
Bausch Health Seeking To Refinance Existing Credit Agreement And Conditional Redemption Of Existing Notes
12/6/2021 7:01:17 AM
Bausch Health : APMA Grants Seal Of Approval For JUBLIA Topical Solution, 10%
11/2/2021 7:23:54 AM
Bausch Health Companies Q3 Net Income $188 Mln Up From $71 Mln Last Year
11/1/2021 7:18:40 AM
Bausch + Lomb To Present Data During American Academy Of Ophthalmology & American Academy Of Optometry Meetings
10/25/2021 6:47:09 AM
Bausch + Lomb,Clearside Biomedical: FDA Approves XIPERE For Suprachoroidal Use For Macular Edema Associated With Uveitis
10/21/2021 7:12:13 AM
Bausch Health Says Tom Vadaketh Will Join Bausch Pharma As CFO
10/19/2021 7:04:29 AM
Ortho Dermatologics To Present New Data At 2021 Fall Clinical Dermatology Conference
9/30/2021 7:40:25 AM
Bausch Health Says Phase 3 Trial Of NOV03 Meets End Points In Dry Eye Disease
9/30/2021 7:06:57 AM
Bausch + Lomb Unveils Significant Topline Results From II Phase 3 Trial Of NOV03 In Dry Eye Disease Associated With MGD
9/29/2021 7:07:44 AM
Bausch Health Releases Annual Environmental, Social And Governance Report
9/2/2021 7:03:24 AM
Salix Pharma To Share RELISTOR Or Methylnaltrexone Bromide Data At PAINWeek 2021
8/4/2021 6:57:24 AM
Bausch Health : Health Canada Approves ARAZLO Lotion, 0.045%, First Such Lotion Treatment For Acne Vulgaris
8/3/2021 7:23:51 AM
Bausch Health Companies Reports Q2 Net Loss Of $595 Mln, Revenues Of $2.100 Bln
8/3/2021 7:18:47 AM
Bausch Health Plans To Pursue IPO Of Solta Medical